Among patients with UC, those treated with GLP1RA had lower rates of corticosteroid use (39.9% vs 76.0%), emergency department visits (41.9% vs 52.7%), hospitalization (30.6% vs 55.8%), intestinal resection (17.8% vs 53.9%), and mortality (5.8% vs 10.9%)
Kato, M., Nishikawa, S., Ikehata, A., Dochi, K., Tani, T., Takahashi, T., & Tsuda, T
Elderly patients, those with irregular meal patterns, renal impairment, or taking multiple glucose-lowering agents face heightened risk
The medications are Ozempic, Wegovy, and Rybelsus, which are manufactured by Novo Nordisk, and Trulicity and Mounjaro, which are manufactured by Eli Lilly & Co
For Active Individuals: Protecting Performance If youre athletic or highly active, you may notice temporary changes in your performance while using GLP-1 medications
Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature